var data={"title":"Herpes simplex virus infection of the esophagus","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Herpes simplex virus infection of the esophagus</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/contributors\" class=\"contributor contributor_credentials\">Peter A L Bonis, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/contributors\" class=\"contributor contributor_credentials\">Dori F Zaleznik, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/contributors\" class=\"contributor contributor_credentials\">Martin S Hirsch, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/contributors\" class=\"contributor contributor_credentials\">Jennifer Mitty, MD, MPH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Jul 21, 2016.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Esophagitis is most often caused by noninfectious conditions, such as gastroesophageal reflux disease, whereas esophageal infection occurs predominantly in hosts with impaired immunity resulting from chemotherapy, transplantation, or HIV infection. The most common causes of infectious esophagitis include candida, cytomegalovirus (CMV), and herpes simplex virus (HSV).</p><p>This topic will address the epidemiology, clinical manifestations, diagnosis, and treatment of HSV esophagitis. Topics on candidal and CMV esophagitis are found elsewhere. (See <a href=\"topic.htm?path=clinical-manifestations-of-oropharyngeal-and-esophageal-candidiasis\" class=\"medical medical_review\">&quot;Clinical manifestations of oropharyngeal and esophageal candidiasis&quot;</a> and <a href=\"topic.htm?path=aids-related-cytomegalovirus-gastrointestinal-disease\" class=\"medical medical_review\">&quot;AIDS-related cytomegalovirus gastrointestinal disease&quot;</a> and <a href=\"topic.htm?path=treatment-of-oropharyngeal-and-esophageal-candidiasis\" class=\"medical medical_review\">&quot;Treatment of oropharyngeal and esophageal candidiasis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Herpes simplex virus (HSV) infection of the esophagus is usually observed in patients who are immunocompromised, but can occasionally be seen in patients who are immunocompetent. The vast majority of infections are related to HSV type 1, although HSV-2 has occasionally been reported [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/1,2\" class=\"abstract_t\">1,2</a>]. </p><p>HSV esophagitis may result from reactivation of HSV with spread of virus to the esophageal mucosa by way of the vagus nerve or by direct extension of oral&ndash;pharyngeal infection into the esophagus [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/3\" class=\"abstract_t\">3</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h2\">Immunocompromised hosts</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>HSV esophagitis occurs most frequently in solid organ and bone marrow transplant recipients [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/4-8\" class=\"abstract_t\">4-8</a>]. HSV and cytomegalovirus (CMV) were the most commonly identified pathogens (48 percent each) in a study of 21 patients with endoscopically proven esophagitis who had undergone bone marrow transplantation [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/9\" class=\"abstract_t\">9</a>]. HSV esophagitis has also been reported in the setting of acute rejection and intensive immunosuppression [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/5\" class=\"abstract_t\">5</a>].</p><p>HSV is a less common cause of esophagitis in patients with HIV infection than in transplant recipients. In three illustrative reports, esophagitis from HSV-1 infection was identified in only 3 to 5 percent of HIV-infected patients with esophagitis [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/9-11\" class=\"abstract_t\">9-11</a>]. In most reports, the most common cause of esophagitis in patients with advanced AIDS was candida, whereas the most common viral cause was CMV [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/11\" class=\"abstract_t\">11</a>]. Both infections coexist in some patients. However, the incidence of infectious esophagitis from any cause has declined since the introduction of potent antiretroviral therapy. (See <a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-herpes-simplex-virus-type-1-infection\" class=\"medical medical_review\">&quot;Clinical manifestations and diagnosis of herpes simplex virus type 1 infection&quot;</a> and <a href=\"topic.htm?path=clinical-manifestations-of-oropharyngeal-and-esophageal-candidiasis\" class=\"medical medical_review\">&quot;Clinical manifestations of oropharyngeal and esophageal candidiasis&quot;</a> and <a href=\"topic.htm?path=factors-affecting-hiv-progression#H25\" class=\"medical medical_review\">&quot;Factors affecting HIV progression&quot;, section on 'Impact of treatment'</a>.)</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h2\">Immunocompetent patients</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Esophagitis due to HSV-1 has been described in otherwise healthy patients in case reports [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/1,12-19\" class=\"abstract_t\">1,12-19</a>]. In a review of 56 patients (39 men and 17 women), the mean age at presentation was 35 years with cases among men predominating in those under 40 years of age [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/1\" class=\"abstract_t\">1</a>]. One series suggested an association between HSV esophagitis and eosinophilic esophagitis [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/20\" class=\"abstract_t\">20</a>]. Cases of HSV-1 esophagitis have also been reported in immunocompetent children [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/13,14\" class=\"abstract_t\">13,14</a>]. HSV-2 is also a rare but reported cause of HSV esophagitis in immunocompetent patients [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/2\" class=\"abstract_t\">2</a>].</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">CLINICAL MANIFESTATIONS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients usually present with odynophagia <span class=\"nowrap\">and/or</span> dysphagia [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/1,21\" class=\"abstract_t\">1,21</a>]. In the review of 56 immunocompetent patients, fever and retrosternal chest pain occurred in 52 and 46 percent, respectively [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/1\" class=\"abstract_t\">1</a>]. These latter symptoms are also a feature of herpes simplex virus (HSV) esophagitis in immunocompromised individuals. Patients can have coexistent herpes labialis or oropharyngeal ulcers [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/22\" class=\"abstract_t\">22</a>]. Complications that have been described in older case reports include bleeding [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/23\" class=\"abstract_t\">23</a>], the development of a tracheoesophageal fistula [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/24,25\" class=\"abstract_t\">24,25</a>], and food impaction [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/26\" class=\"abstract_t\">26</a>]. Intractable hiccups in association with HSV esophagitis has also been described [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/27,28\" class=\"abstract_t\">27,28</a>].</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of herpes simplex virus (HSV) esophagitis is usually based on endoscopic findings confirmed by histopathological examination of the observed lesions. Suggestive findings may sometimes be seen during a <a href=\"topic.htm?path=barium-drug-information\" class=\"drug drug_general\">barium</a> swallow (<a href=\"image.htm?imageKey=GAST%2F60135\" class=\"graphic graphic_diagnosticimage graphicRef60135 \">image 1</a>).</p><p>Lesions usually affect the squamous mucosa of the distal esophagus where the earliest manifestation is a vesicle, although this early stage is rarely seen on endoscopy. The lesions coalesce to form ulcers (usually less than 2 cm), frequently with normal-appearing intervening mucosa (<a href=\"image.htm?imageKey=ID%2F83681\" class=\"graphic graphic_picture graphicRef83681 \">picture 1</a>). The ulcers are well circumscribed and have a &quot;volcano-like&quot; appearance, distinguishing them from the ulcers seen in cytomegalovirus (CMV) infection, which tend to be linear or longitudinal and deeper [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/4,29\" class=\"abstract_t\">4,29</a>]. Exudates, plaques, or diffuse erosive esophagitis may also be present [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/30\" class=\"abstract_t\">30</a>].</p><p>Biopsies or brushing should be taken from the edge of an ulcer where viral cytopathic effects are most likely to be present. Histologic findings include multinucleated giant cells, with ground-glass nuclei and eosinophilic inclusions (Cowdry type A inclusion bodies) that occupy up to one-half of the nuclear volume (<a href=\"image.htm?imageKey=GAST%2F67790\" class=\"graphic graphic_picture graphicRef67790 \">picture 2</a>) [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/31\" class=\"abstract_t\">31</a>]. Immunohistochemical stains for HSV glycoproteins may also be helpful [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/32\" class=\"abstract_t\">32</a>]. Viral culture of suspicious lesions should be performed during endoscopy to confirm the diagnosis and to identify resistant viral isolates in patients who do not respond to <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a>.</p><p>Qualitative and quantitative polymerase chain reaction (PCR) testing has been investigated to detect HSV DNA from biopsy samples [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/32,33\" class=\"abstract_t\">32,33</a>]. Efforts are also being made to assess whether determining a tissue viral load could improve specificity and positive predictive values from PCR testing [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/32\" class=\"abstract_t\">32</a>]. </p><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The differential diagnosis includes other infectious causes of esophagitis (mainly cytomegalovirus [CMV] and candida). Although candida is the most common fungal cause of esophagitis, other fungal infections, including cryptococcosis, histoplasmosis, blastomycosis, and aspergillosis have rarely been described [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/34\" class=\"abstract_t\">34</a>]. Other pathogens, such as mycobacteria and nocardia, have occasionally been reported [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/34,35\" class=\"abstract_t\">34,35</a>]. In patients with advanced HIV infection, idiopathic aphthous ulcers have been described in up to one-fourth of patients with esophageal symptoms who did not respond to empiric antifungal therapy [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/11\" class=\"abstract_t\">11</a>]. (See <a href=\"topic.htm?path=clinical-manifestations-of-oropharyngeal-and-esophageal-candidiasis\" class=\"medical medical_review\">&quot;Clinical manifestations of oropharyngeal and esophageal candidiasis&quot;</a>.)</p><p>Other diagnostic considerations include noninfectious causes of esophagitis, particularly pill esophagitis. (See <a href=\"topic.htm?path=medication-induced-esophagitis\" class=\"medical medical_review\">&quot;Medication-induced esophagitis&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The management of herpes simplex virus (HSV) esophagitis depends upon the host's underlying immune status.</p><p class=\"headingAnchor\" id=\"H9\"><span class=\"h2\">Immunocompromised hosts</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Immunocompromised hosts should be treated with a longer duration of therapy than is typically given for less invasive HSV infection (ie, genital HSV). For immunosuppressed patients able to take oral medications, <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> (400 mg PO five times a day for 14 to 21 days) is effective and has few side effects. (See <a href=\"topic.htm?path=acyclovir-an-overview\" class=\"medical medical_review\">&quot;Acyclovir: An overview&quot;</a>.)</p><p><a href=\"topic.htm?path=famciclovir-drug-information\" class=\"drug drug_general\">Famciclovir</a> (500 mg three times daily) or <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a> (1 gram three times daily) can also be considered in patients able to tolerate oral therapy, although there is limited experience with these drugs in HSV esophagitis. Famciclovir and valacyclovir are considered comparable in potency in the treatment of other HSV infections and have the advantage of decreased pill burden; however, they are generally more expensive than <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a>. (See <a href=\"topic.htm?path=famciclovir-an-overview\" class=\"medical medical_review\">&quot;Famciclovir: An overview&quot;</a> and <a href=\"topic.htm?path=valacyclovir-an-overview\" class=\"medical medical_review\">&quot;Valacyclovir: An overview&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H10\"><span class=\"h2\">Immunocompetent hosts</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Spontaneous resolution usually occurs in immunocompetent hosts after one to two weeks, although patients may respond more quickly if treated with a short course of oral <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a>. While there are no trials of acyclovir in immunocompetent patients with HSV-1 esophagitis, case reports of patient with HSV esophagitis [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/2\" class=\"abstract_t\">2</a>], and treatment experience with acyclovir in immunocompetent patients with oral and genital herpes suggest therapeutic benefit in hastening resolution of lesions. Symptoms have been reported to respond promptly and acyclovir has proven safe in immunocompetent patients treated with other herpes infections. In patients who are <strong>not</strong> immunocompromised, we suggest treatment with a short course of oral acyclovir (200 mg PO five times a day or 400 mg PO three times a day for 7 to 10 days) unless symptoms already appear to be abating.</p><p><a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">Acyclovir</a> is generally well tolerated. (See <a href=\"topic.htm?path=acyclovir-an-overview\" class=\"medical medical_review\">&quot;Acyclovir: An overview&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H11\"><span class=\"h2\">Treatment of patients with severe odynophagia or dysphagia</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with severe odynophagia may require hospitalization for parenteral antiviral therapy, pain management, and hydration or alimentation. Treatment can include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Intravenous (IV) <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> (5 <span class=\"nowrap\">mg/kg</span> IV every eight hours for 7 to 14 days) can be administered to those who are unable to swallow. Patients who rapidly improve can be switched to oral therapy to complete their therapeutic course. Shortages of IV acyclovir have occurred. If IV acyclovir is not available, alternative agents must be used. Specific recommendations are presented separately. (See <a href=\"topic.htm?path=acyclovir-an-overview#H620875503\" class=\"medical medical_review\">&quot;Acyclovir: An overview&quot;, section on 'If there is an acyclovir shortage'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Swallowed viscous <a href=\"topic.htm?path=lidocaine-drug-information\" class=\"drug drug_general\">lidocaine</a> oral topical solution (15 mL of a 2 percent formulation) with or without an antacid can be tried to relieve pain [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/36\" class=\"abstract_t\">36</a>], but in our experience is usually only of modest benefit. About 35 percent of the dose is absorbed; thus ingestion should be limited to no more than 300 mg lidocaine (viscous) per dose for patients weighing greater than 65 kg and 4.5 <span class=\"nowrap\">mg/kg</span> lidocaine (viscous) per dose for patients weighing 65 kg or less, and no more than eight doses per day [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/37\" class=\"abstract_t\">37</a>].</p><p/><p class=\"headingAnchor\" id=\"H12\"><span class=\"h2\">Drug-resistant HSV</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients who do not respond to therapy may have virus resistant to <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> resulting from mutations within the thymidine kinase (TK) or, less commonly, the DNA polymerase gene of HSV [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/38\" class=\"abstract_t\">38</a>]. Viruses with TK mutations are generally cross-resistant to other drugs in this class, including <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a> and <a href=\"topic.htm?path=famciclovir-drug-information\" class=\"drug drug_general\">famciclovir</a>, but remain susceptible to antiviral agents that act directly on DNA polymerase (eg, <a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">foscarnet</a>) [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/39\" class=\"abstract_t\">39</a>].</p><p>Most experience with <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> resistance is related to HSV oral mucositis or genital infection. Acyclovir resistance is most commonly seen in immunocompromised patients, those who have undergone chemotherapy, transplantation, or who have HIV infection [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/40-42\" class=\"abstract_t\">40-42</a>]. Many of these patients will have received multiple courses of acyclovir in the past. Resistant HSV can also arise spontaneously from natural variations within the viral population; this is evident from studies that have demonstrated acyclovir resistance in treatment-naive patients [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/41\" class=\"abstract_t\">41</a>]. However, in extensive surveys conducted in the United States and the United Kingdom of immunocompetent hosts, isolation of drug-resistant HSV remains low (approximately 0.1 to 0.7 percent of isolates). Low levels of drug resistance have been attributed to rapid clearing of HSV infection by an intact immune system [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/43\" class=\"abstract_t\">43</a>].</p><p>Cases of severe persistent infection with acyclovir-resistant HSV occur almost exclusively in immunocompromised hosts [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/43\" class=\"abstract_t\">43</a>]; in immunocompetent hosts, rare cases of drug-resistant virus have cleared without adverse clinical outcome [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/43\" class=\"abstract_t\">43</a>].</p><p>Treatment with <a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">foscarnet</a> can be effective for immunosuppressed patients with HSV strains known to be resistant to <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> or for those who do not respond to acyclovir, although foscarnet must be given parenterally and is associated with considerable toxicity [<a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/44,45\" class=\"abstract_t\">44,45</a>]. (See <a href=\"topic.htm?path=foscarnet-an-overview\" class=\"medical medical_review\">&quot;Foscarnet: An overview&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H13\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Herpes simplex virus (HSV) infection of the esophagus is usually observed in patients who are immunocompromised and occurs most frequently in those receiving immunosuppressive agents, such as solid organ and bone marrow transplant recipients. However, it has also been described in otherwise healthy patients. (See <a href=\"#H4\" class=\"local\">'Immunocompetent patients'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients usually present with odynophagia and dysphagia. Fever, epigastric pain, nausea, vomiting, and heartburn are less frequent. Occasional patients have coexistent herpes labialis or oropharyngeal ulcers.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Diagnosis is usually established with an upper endoscopy. Biopsies or brushing should be taken from the edge of an ulcer where viral cytopathic effects are most likely to be present. (See <a href=\"#H6\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The differential diagnosis includes other forms of infectious esophagitis, and pill esophagitis. (See <a href=\"#H7\" class=\"local\">'Differential diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients who are NOT immunocompromised, we suggest treatment with a short course of oral <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">acyclovir</a> (200 mg PO five times a day or 400 mg PO three times a day for 7 to 10 days) unless symptoms already appear to be abating (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). (See <a href=\"#H4\" class=\"local\">'Immunocompetent patients'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>In patients who are immunocompromised, we recommend antiviral therapy for 14 to 21 days (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>). <a href=\"topic.htm?path=acyclovir-drug-information\" class=\"drug drug_general\">Acyclovir</a> (400 mg PO five times a day) has potent anti-HSV activity and is generally the least expensive agent. <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">Valacyclovir</a> or <a href=\"topic.htm?path=famciclovir-drug-information\" class=\"drug drug_general\">famciclovir</a> afford less frequent dosing if patient adherence is a concern. Intravenous acyclovir (5 <span class=\"nowrap\">mg/kg</span> IV every eight hours for 7 to 14 days) can be used for those who are unable to swallow. (See <a href=\"#H3\" class=\"local\">'Immunocompromised hosts'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Drug-resistant virus should be suspected in patients who do not respond to antiviral therapy within approximately five to seven days. Viruses with thymidine kinase mutations are generally cross-resistant to other drugs in this class, including <a href=\"topic.htm?path=valacyclovir-drug-information\" class=\"drug drug_general\">valacyclovir</a> and <a href=\"topic.htm?path=famciclovir-drug-information\" class=\"drug drug_general\">famciclovir</a>, but remain susceptible to antiviral agents that act directly on DNA polymerase (eg, <a href=\"topic.htm?path=foscarnet-drug-information\" class=\"drug drug_general\">foscarnet</a>). (See <a href=\"#H12\" class=\"local\">'Drug-resistant HSV'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/1\" class=\"nounderline abstract_t\">Canalejo Castrillero E, Garc&iacute;a Dur&aacute;n F, Cabello N, Garc&iacute;a Mart&iacute;nez J. Herpes esophagitis in healthy adults and adolescents: report of 3 cases and review of the literature. Medicine (Baltimore) 2010; 89:204.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/2\" class=\"nounderline abstract_t\">Kadayakkara DK, Candelaria A, Kwak YE, Loeser C. Herpes Simplex Virus-2 Esophagitis in a Young Immunocompetent Adult. Case Rep Gastrointest Med 2016; 2016:7603484.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/3\" class=\"nounderline abstract_t\">Corey L, Spear PG. Infections with herpes simplex viruses (2). N Engl J Med 1986; 314:749.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/4\" class=\"nounderline abstract_t\">McBane RD, Gross JB Jr. Herpes esophagitis: clinical syndrome, endoscopic appearance, and diagnosis in 23 patients. Gastrointest Endosc 1991; 37:600.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/5\" class=\"nounderline abstract_t\">Mosimann F, Cu&eacute;noud PF, Steinh&auml;uslin F, Wauters JP. Herpes simplex esophagitis after renal transplantation. Transpl Int 1994; 7:79.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/6\" class=\"nounderline abstract_t\">McDonald GB, Sharma P, Hackman RC, et al. Esophageal infections in immunosuppressed patients after marrow transplantation. Gastroenterology 1985; 88:1111.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/7\" class=\"nounderline abstract_t\">Kang YN, Oh HK, Chang YC, et al. Systemic herpes simplex virus infection following cadaveric renal transplantation: a case report. Transplant Proc 2006; 38:1346.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/8\" class=\"nounderline abstract_t\">Eisen HJ, Kobashigawa J, Keogh A, et al. Three-year results of a randomized, double-blind, controlled trial of mycophenolate mofetil versus azathioprine in cardiac transplant recipients. J Heart Lung Transplant 2005; 24:517.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/9\" class=\"nounderline abstract_t\">Wilcox CM, Schwartz DA, Clark WS. Esophageal ulceration in human immunodeficiency virus infection. Causes, response to therapy, and long-term outcome. Ann Intern Med 1995; 123:143.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/10\" class=\"nounderline abstract_t\">Bonacini M, Young T, Laine L. The causes of esophageal symptoms in human immunodeficiency virus infection. A prospective study of 110 patients. Arch Intern Med 1991; 151:1567.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/11\" class=\"nounderline abstract_t\">Bini EJ, Micale PL, Weinshel EH. Natural history of HIV-associated esophageal disease in the era of protease inhibitor therapy. Dig Dis Sci 2000; 45:1301.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/12\" class=\"nounderline abstract_t\">Ramanathan J, Rammouni M, Baran J Jr, Khatib R. Herpes simplex virus esophagitis in the immunocompetent host: an overview. Am J Gastroenterol 2000; 95:2171.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/13\" class=\"nounderline abstract_t\">Rodrigues F, Brand&atilde;o N, Duque V, et al. Herpes simplex virus esophagitis in immunocompetent children. J Pediatr Gastroenterol Nutr 2004; 39:560.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/14\" class=\"nounderline abstract_t\">Boersma CC, Borowitz SM. Odynophagia. Clin Pediatr (Phila) 2007; 46:556.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/15\" class=\"nounderline abstract_t\">Nagri S, Hwang R, Anand S, Kurz J. Herpes simplex esophagitis presenting as acute necrotizing esophagitis (&quot;black esophagus&quot;) in an immunocompetent patient. Endoscopy 2007; 39 Suppl 1:E169.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/16\" class=\"nounderline abstract_t\">Lee B, Caddy G. A rare cause of dysphagia: herpes simplex esophagitis. World J Gastroenterol 2007; 13:2756.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/17\" class=\"nounderline abstract_t\">Geraci G, Pisello F, Modica G, et al. Herpes simplex esophagitis in immunocompetent host: a case report. Diagn Ther Endosc 2009; 2009:717183.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/18\" class=\"nounderline abstract_t\">Bando T, Matsushita M, Kitano M, Okazaki K. Herpes simplex esophagitis in the elderly. Dig Endosc 2009; 21:205.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/19\" class=\"nounderline abstract_t\">Marinho AV, Bonfim VM, de Alencar LR, et al. Herpetic esophagitis in immunocompetent medical student. Case Rep Infect Dis 2014; 2014:930459.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/20\" class=\"nounderline abstract_t\">Zimmermann D, Criblez DH, Dellon ES, et al. Acute Herpes Simplex Viral Esophagitis Occurring in 5 Immunocompetent Individuals With Eosinophilic Esophagitis. ACG Case Rep J 2016; 3:165.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/21\" class=\"nounderline abstract_t\">G&eacute;n&eacute;reau T, Lortholary O, Bouchaud O, et al. Herpes simplex esophagitis in patients with AIDS: report of 34 cases. The Cooperative Study Group on Herpetic Esophagitis in HIV Infection. Clin Infect Dis 1996; 22:926.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/22\" class=\"nounderline abstract_t\">Baehr PH, McDonald GB. Esophageal infections: risk factors, presentation, diagnosis, and treatment. Gastroenterology 1994; 106:509.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/23\" class=\"nounderline abstract_t\">Rattner HM, Cooper DJ, Zaman MB. Severe bleeding from herpes esophagitis. Am J Gastroenterol 1985; 80:523.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/24\" class=\"nounderline abstract_t\">Obrecht WF Jr, Richter JE, Olympio GA, Gelfand DW. Tracheoesophageal fistula: a serious complication of infectious esophagitis. Gastroenterology 1984; 87:1174.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/25\" class=\"nounderline abstract_t\">Cirillo NW, Lyon DT, Schuller AM. Tracheoesophageal fistula complicating herpes esophagitis in AIDS. Am J Gastroenterol 1993; 88:587.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/26\" class=\"nounderline abstract_t\">Marshall JB, Smart JR 3rd, Elmer C, et al. Herpes esophagitis causing an unsuspected esophageal food bolus impaction in an institutionalized patient. J Clin Gastroenterol 1992; 15:179.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/27\" class=\"nounderline abstract_t\">Mulhall BP, Nelson B, Rogers L, Wong RK. Herpetic esophagitis and intractable hiccups (singultus) in an immunocompetent patient. Gastrointest Endosc 2003; 57:796.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/28\" class=\"nounderline abstract_t\">Harris J, Smith T, Preis J. Intractable hiccups due to herpetic esophagitis in an immunocompromised patient. IDCases 2016; 4:34.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/29\" class=\"nounderline abstract_t\">Levine MS. Radiology of esophagitis: a pattern approach. Radiology 1991; 179:1.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/30\" class=\"nounderline abstract_t\">Wong RC, Abdul-Karim FW. Atypical herpes simplex esophagitis. Gastrointest Endosc 2005; 61:291.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/31\" class=\"nounderline abstract_t\">Wilcox CM, Rodgers W, Lazenby A. Prospective comparison of brush cytology, viral culture, and histology for the diagnosis of ulcerative esophagitis in AIDS. Clin Gastroenterol Hepatol 2004; 2:564.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/32\" class=\"nounderline abstract_t\">Jazeron JF, Barbe C, Frobert E, et al. Virological diagnosis of herpes simplex virus 1 esophagitis by quantitative real-time PCR assay. J Clin Microbiol 2012; 50:948.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/33\" class=\"nounderline abstract_t\">Dekeyser S, El Nady M, Diaz E, et al. [Diagnosis of herpetic esophagitis in the immunocompetent subject by PCR (Herp&egrave;s Consensus G&eacute;n&eacute;rique-Arg&egrave;ne). Report of six cases]. Pathol Biol (Paris) 2009; 57:101.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/34\" class=\"nounderline abstract_t\">Sutton FM, Graham DY, Goodgame RW. Infectious esophagitis. Gastrointest Endosc Clin N Am 1994; 4:713.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/35\" class=\"nounderline abstract_t\">El-Serag HB, Johnston DE. Mycobacterium avium complex esophagitis. Am J Gastroenterol 1997; 92:1561.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/36\" class=\"nounderline abstract_t\">Shortsleeve MJ, Levine MS. Herpes esophagitis in otherwise healthy patients: clinical and radiographic findings. Radiology 1992; 182:859.</a></li><li class=\"breakAll\">USP-FDA package insert (adult dosing section). http://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?id=4124&amp;type=display (Accessed on August 12, 2008).</li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/38\" class=\"nounderline abstract_t\">Frobert E, Ooka T, Cortay JC, et al. Herpes simplex virus thymidine kinase mutations associated with resistance to acyclovir: a site-directed mutagenesis study. Antimicrob Agents Chemother 2005; 49:1055.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/39\" class=\"nounderline abstract_t\">Pelosi E, Mulamba GB, Coen DM. Penciclovir and pathogenesis phenotypes of drug-resistant Herpes simplex virus mutants. Antiviral Res 1998; 37:17.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/40\" class=\"nounderline abstract_t\">Malvy D, Treilhaud M, Bou&eacute;e S, et al. A retrospective, case-control study of acyclovir resistance in herpes simplex virus. Clin Infect Dis 2005; 41:320.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/41\" class=\"nounderline abstract_t\">Kriesel JD, Spruance SL, Prichard M, et al. Recurrent antiviral-resistant genital herpes in an immunocompetent patient. J Infect Dis 2005; 192:156.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/42\" class=\"nounderline abstract_t\">Str&aacute;nsk&aacute; R, Schuurman R, Nienhuis E, et al. Survey of acyclovir-resistant herpes simplex virus in the Netherlands: prevalence and characterization. J Clin Virol 2005; 32:7.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/43\" class=\"nounderline abstract_t\">Levin MJ, Bacon TH, Leary JJ. Resistance of herpes simplex virus infections to nucleoside analogues in HIV-infected patients. Clin Infect Dis 2004; 39 Suppl 5:S248.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/44\" class=\"nounderline abstract_t\">Erlich KS, Mills J, Chatis P, et al. Acyclovir-resistant herpes simplex virus infections in patients with the acquired immunodeficiency syndrome. N Engl J Med 1989; 320:293.</a></li><li><a href=\"https://www.uptodate.com/contents/herpes-simplex-virus-infection-of-the-esophagus/abstract/45\" class=\"nounderline abstract_t\">Chatis PA, Miller CH, Schrager LE, Crumpacker CS. Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome. N Engl J Med 1989; 320:297.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 8306 Version 11.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H13\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY</a><ul><li><a href=\"#H3\" id=\"outline-link-H3\">Immunocompromised hosts</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">Immunocompetent patients</a></li></ul></li><li><a href=\"#H5\" id=\"outline-link-H5\">CLINICAL MANIFESTATIONS</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">DIAGNOSIS</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">TREATMENT</a><ul><li><a href=\"#H9\" id=\"outline-link-H9\">Immunocompromised hosts</a></li><li><a href=\"#H10\" id=\"outline-link-H10\">Immunocompetent hosts</a></li><li><a href=\"#H11\" id=\"outline-link-H11\">Treatment of patients with severe odynophagia or dysphagia</a></li><li><a href=\"#H12\" id=\"outline-link-H12\">Drug-resistant HSV</a></li></ul></li><li><a href=\"#H13\" id=\"outline-link-H13\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/8306|DiagnosticImage\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"DIAGNOSTIC IMAGES\">DIAGNOSTIC IMAGES</a></div><ul><li><a href=\"image.htm?imageKey=GAST/60135\" class=\"graphic graphic_diagnosticimage\">- Herpes esophagitis Ba swallow</a></li></ul></li><li><div id=\"ID/8306|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/83681\" class=\"graphic graphic_picture\">- Endoscopy showing ulcers</a></li><li><a href=\"image.htm?imageKey=GAST/67790\" class=\"graphic graphic_picture\">- Herpes esophagitis Light</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=aids-related-cytomegalovirus-gastrointestinal-disease\" class=\"medical medical_review\">AIDS-related cytomegalovirus gastrointestinal disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=acyclovir-an-overview\" class=\"medical medical_review\">Acyclovir: An overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-and-diagnosis-of-herpes-simplex-virus-type-1-infection\" class=\"medical medical_review\">Clinical manifestations and diagnosis of herpes simplex virus type 1 infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=clinical-manifestations-of-oropharyngeal-and-esophageal-candidiasis\" class=\"medical medical_review\">Clinical manifestations of oropharyngeal and esophageal candidiasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=factors-affecting-hiv-progression\" class=\"medical medical_review\">Factors affecting HIV progression</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=famciclovir-an-overview\" class=\"medical medical_review\">Famciclovir: An overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=foscarnet-an-overview\" class=\"medical medical_review\">Foscarnet: An overview</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=medication-induced-esophagitis\" class=\"medical medical_review\">Medication-induced esophagitis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=treatment-of-oropharyngeal-and-esophageal-candidiasis\" class=\"medical medical_review\">Treatment of oropharyngeal and esophageal candidiasis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=valacyclovir-an-overview\" class=\"medical medical_review\">Valacyclovir: An overview</a></li></ul></div></div>","javascript":null}